Hexima

Hexima Limited is a biotechnology company actively engaged in the research and development of plant-derived molecules for use in human health and agriculture.

Learn more

Investor

For information relating to investor updates, financial information, share trading and presentations click the link below.

Investor News

Science

Hexima is developing technology for use in transgenic plants to prevent damage by fungal pathogens and insect pests and for the treatment of fungal infections and non-melanoma skin cancer in humans.

Learn more

Upcoming CEO Presentations

Shareholders are invited to attend a presentation by Hexima CEO Dr Nicole van der Weerden. To view a copy of the presentation click here. Dr van der Weerden will present in Melbourne on Monday 26th June at 11am at Lvl 21, 333 Collins Street (offices of Arnold Bloch Liebler). A second presentation will be held in Sydney in the near future, with further details to be advised.

Hexima Shareholder Update and Share Trading

Hexima is pleased to advise that it has completed a pivotal GLP repeat-dose dermal irritation study in minipigs for HPX124 which should provide sufficient pre-clinical animal toxicology data to support a first-in-human clinical trial for HXP124 as a treatment of onychomycosis. Further details are provided in the presentation.

Hexima Rights Issue Completed

Dear Shareholders I am pleased to inform you that the Hexima Rights Issue successfully closed last week with an overall take-up through entitlements and oversubscriptions of 65.4%.  This result was very encouraging and Hexima is grateful to all shareholders who...

Extension of Hexima’s rights issue offer

Hexima Limited ACN 079 319 314 (Company) wishes to advise shareholders that it is extending the invitation for shareholders to participate in the rights issue of 6 new shares for every 10 shares which shareholders held on the relevant record date (Offer), under the...

Hexima Prospectus Rights Issue

Hexima is pleased to offer each existing shareholder the opportunity to participate in a fully underwritten non-renounceable pro-rata offer to subscribe for 6 New Shares for every 10 Shares held on the Record Date to raise a maximum amount of $3,896,663 (before costs...

External Links

Take a look at these useful links to learn more about our industry.